With Friday’s approval, Sanofi’s Sarclisa will go head-to-head with Johnson & Johnson’s Darzalex, which is the first anti-CD38 monoclonal antibody for multiple myeloma and raked in nearly $10 billion for J&J last year.
With Friday’s approval, Sanofi’s Sarclisa will go head-to-head with Johnson & Johnson’s Darzalex, which is the first anti-CD38 monoclonal antibody for multiple myeloma and raked in nearly $10 billion for J&J last year.